n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies.

Biomarkers Cohort Studies Diabetes Mellitus, Type 2 / epidemiology Docosahexaenoic Acids Eicosapentaenoic Acid Fatty Acids, Omega-3 Humans Prospective Studies

Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
05 2021
Historique:
received: 30 09 2020
accepted: 04 02 2021
pubmed: 5 3 2021
medline: 23 9 2021
entrez: 4 3 2021
Statut: ppublish

Résumé

Prospective associations between n-3 fatty acid biomarkers and type 2 diabetes (T2D) risk are not consistent in individual studies. We aimed to summarize the prospective associations of biomarkers of α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with T2D risk through an individual participant-level pooled analysis. For our analysis we incorporated data from a global consortium of 20 prospective studies from 14 countries. We included 65,147 participants who had blood measurements of ALA, EPA, DPA, or DHA and were free of diabetes at baseline. De novo harmonized analyses were performed in each cohort following a prespecified protocol, and cohort-specific associations were pooled using inverse variance-weighted meta-analysis. A total of 16,693 incident T2D cases were identified during follow-up (median follow-up ranging from 2.5 to 21.2 years). In pooled multivariable analysis, per interquintile range (difference between the 90th and 10th percentiles for each fatty acid), EPA, DPA, DHA, and their sum were associated with lower T2D incidence, with hazard ratios (HRs) and 95% CIs of 0.92 (0.87, 0.96), 0.79 (0.73, 0.85), 0.82 (0.76, 0.89), and 0.81 (0.75, 0.88), respectively (all Higher circulating biomarkers of seafood-derived n-3 fatty acids, including EPA, DPA, DHA, and their sum, were associated with lower risk of T2D in a global consortium of prospective studies. The biomarker of plant-derived ALA was not significantly associated with T2D risk.

Identifiants

DOI: 10.2337/dc20-2426 PMID: 33658295 PMC: PMC8132316
pubmed: 33658295
pii: dc20-2426
doi: 10.2337/dc20-2426
pmc: PMC8132316
doi:

Substances chimiques

Biomarkers 0
Fatty Acids, Omega-3 0
Docosahexaenoic Acids 25167-62-8
Eicosapentaenoic Acid AAN7QOV9EA

Banques de données

figshare
['10.2337/figshare.13724110']

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1133-1142

Subventions

Organisme : Medical Research Council
ID : MC_UU_00006/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL034594
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00006/3
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL035464
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL088521
Pays : United States

Informations de copyright

© 2021 by the American Diabetes Association.

Références

Mol Nutr Food Res. 2015 Jul;59(7):1373-83
pubmed: 25626431
Lipids Health Dis. 2017 Jul 3;16(1):131
pubmed: 28673352
Nutrients. 2019 Aug 28;11(9):
pubmed: 31466350
Nature. 2014 Jun 5;510(7503):84-91
pubmed: 24899308
BMJ. 2018 Oct 17;363:k4067
pubmed: 30333104
Obes Rev. 2014 Aug;15(8):657-65
pubmed: 24891155
Diabetes Care. 2012 Apr;35(4):918-29
pubmed: 22442397
Exp Mol Med. 2016 Mar 11;48:e220
pubmed: 26964836
Nat Rev Endocrinol. 2011 Nov 08;8(4):228-36
pubmed: 22064493
PLoS Med. 2016 Jul 19;13(7):e1002094
pubmed: 27434045
J Nutr. 2012 Mar;142(3):592S-599S
pubmed: 22279140
Crit Rev Food Sci Nutr. 2014;54(1):98-114
pubmed: 24188235
Lancet. 2014 Jun 7;383(9933):1999-2007
pubmed: 24910231
BMJ. 2019 Jul 25;366:l4292
pubmed: 31345923
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
Nutr J. 2012 Dec 14;11:109
pubmed: 23237668
J Nutr. 2013 Apr;143(4):512-8
pubmed: 23427333
Am J Clin Nutr. 2007 Jul;86(1):74-81
pubmed: 17616765
Cardiovasc Diabetol. 2019 Jun 24;18(1):84
pubmed: 31234885
J Clin Endocrinol Metab. 2016 Oct;101(10):3820-3826
pubmed: 27466884
Nat Med. 2014 Aug;20(8):942-7
pubmed: 24997608
Lancet Diabetes Endocrinol. 2017 Dec;5(12):965-974
pubmed: 29032079
J Nutr. 2018 Nov 1;148(11):1821-1829
pubmed: 30247611
PLoS Med. 2016 Jul 19;13(7):e1002087
pubmed: 27434027
JAMA Intern Med. 2016 Aug 1;176(8):1155-66
pubmed: 27357102
Ann Intern Med. 2014 Jan 7;160(1):1-10
pubmed: 24573661
Nutr Metab Cardiovasc Dis. 2019 Apr;29(4):343-350
pubmed: 30718141
Circulation. 2013 Nov 5;128(19):2154-61
pubmed: 24190935
Adv Nutr. 2018 Jul 1;9(4):378-387
pubmed: 30032229
J Am Coll Cardiol. 2011 Nov 8;58(20):2047-67
pubmed: 22051327
J Clin Endocrinol Metab. 2013 Jun;98(6):2451-9
pubmed: 23703724
BMJ. 2019 Aug 21;366:l4697
pubmed: 31434641
Br J Nutr. 2012 Jun;107 Suppl 2:S214-27
pubmed: 22591895
J Lipid Res. 1997 Oct;38(10):2012-22
pubmed: 9374124
J Physiol Biochem. 2013 Sep;69(3):633-51
pubmed: 23794360
Cell Metab. 2014 Jan 7;19(1):21-36
pubmed: 24239568
Cardiovasc Diabetol. 2018 Jul 7;17(1):98
pubmed: 29981570
Am J Clin Nutr. 2004 May;79(5):765-73
pubmed: 15113713
JAMA. 2016 Oct 11;316(14):1464-1474
pubmed: 27727382
Nutr Rev. 2019 May 24;:
pubmed: 31124569

Auteurs

Frank Qian (F)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
ORCID: 0000-0002-5579-3410

Andres V Ardisson Korat (AV)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Fumiaki Imamura (F)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, U.K.

Matti Marklund (M)

Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA.
The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

Nathan Tintle (N)

Department of Mathematics and Statistics, Dordt University, Sioux Center, IA.
Fatty Acid Research Institute, Sioux Falls, SD.

Jyrki K Virtanen (JK)

Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
ORCID: 0000-0002-0648-999X

Xia Zhou (X)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.

Julie K Bassett (JK)

Cancer Council Victoria, Melbourne, Victoria, Australia.

Heidi Lai (H)

Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA.
Imperial College London, London, U.K.

Yoichiro Hirakawa (Y)

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID: 0000-0002-4405-4399

Kuo-Liong Chien (KL)

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Alexis C Wood (AC)

Children's Nutrition Research Center, U.S. Department of Agriculture/Agricultural Research Service, Houston, TX.

Maria Lankinen (M)

Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.

Rachel A Murphy (RA)

University of British Columbia, Vancouver, British Columbia, Canada.

Cecilia Samieri (C)

INSERM, UMR 1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Kamalita Pertiwi (K)

Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands.
ORCID: 0000-0003-2861-9051

Vanessa D de Mello (VD)

Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
ORCID: 0000-0003-3414-6983

Weihua Guan (W)

Division of Biostatistics, University of Minnesota, Minneapolis, MN.

Nita G Forouhi (NG)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, U.K.
ORCID: 0000-0002-5041-248X

Nick Wareham (N)

MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, U.K.

InterAct Consortium Frank B Hu (ICFB)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Ulf Riserus (U)

Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Lars Lind (L)

Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

William S Harris (WS)

Fatty Acid Research Institute, Sioux Falls, SD.
Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD.

Aladdin H Shadyab (AH)

Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA.

Jennifer G Robinson (JG)

Departments of Epidemiology and Medicine, University of Iowa, Iowa City, IA.

Lyn M Steffen (LM)

Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.

Allison Hodge (A)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Australia.

Graham G Giles (GG)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

Toshiharu Ninomiya (T)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID: 0000-0003-1345-9032

Matti Uusitupa (M)

Fatty Acid Research Institute, Sioux Falls, SD.

Jaakko Tuomilehto (J)

Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.
Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

Jaana Lindström (J)

Public Health Promotion Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.

Markku Laakso (M)

Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
ORCID: 0000-0002-3394-7749

David S Siscovick (DS)

The New York Academy of Medicine, New York, NY.

Catherine Helmer (C)

University of British Columbia, Vancouver, British Columbia, Canada.

Johanna M Geleijnse (JM)

INSERM, UMR 1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Jason H Y Wu (JHY)

The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

Amanda Fretts (A)

Department of Epidemiology, University of Washington School of Public Health, Seattle, WA.

Rozenn N Lemaitre (RN)

Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA.
ORCID: 0000-0002-7038-1844

Renata Micha (R)

Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA.

Dariush Mozaffarian (D)

Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA.
Division of Cardiology, Tufts Medical Center, Boston, MA.

Qi Sun (Q)

ORCID: 0000-0002-8480-1563

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide docosahexaénoïque › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › Acide eicosapentanoïque › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Lipides › Huiles › Huiles de poisson › Acides gras omega-3 › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › n-3 Fatty Acid Biomarkers and Incident Type 2...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › n-3 Fatty Acid Biomarkers and Incident Type 2...